{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T07:11:39Z","timestamp":1788246699485,"version":"build-2803163510"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T00:00:00Z","timestamp":1626998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T00:00:00Z","timestamp":1626998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Allergy Asthma Clin Immunol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hereditary angioedema (HAE) is a rare autosomal dominant disease resulting in recurring episodes of swelling, leading to considerable patient morbidity and mortality. Lanadelumab is a plasma kallikrein inhibitor that is approved as 1st line therapy in Canada for long term prophylaxis of HAE attacks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To describe our clinical findings from a case series of adult patients with HAE type 1\/2 who have been initiated on lanadelumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A chart review of HAE type 1\/2 patients at three academic centers in Canada was undertaken with demographic and clinical data extracted. Patients were included if they had been receiving lanadelumab for at least 6\u00a0months. Patients with other causes of angioedema were excluded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>12 patients meeting enrollment criteria were identified. Compared to pre-lanadelumab, patients had mean reductions of 72% and 62% in attack rate and treated attack rate respectively. 3 patients reported complete remission from attacks after starting lanadelumab. Most patients had significant improvements in HAE impact on social outings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our case series findings support the 2019 International\/Canadian HAE guideline that lanadelumab is an effective therapy for long term prophylaxis. In our patient population, initiation of lanadelumab improved disease control, minimized the burden of treatment and improved HAE impact on social outings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13223-021-00579-6","type":"journal-article","created":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T13:03:02Z","timestamp":1627045382000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Impact of lanadelumab in hereditary angioedema: a case series of 12 patients in Canada"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2671-0815","authenticated-orcid":false,"given":"Aled","family":"Iaboni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Kanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Lacuesta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manstein","family":"Kan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Betschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,23]]},"reference":[{"key":"579_CR1","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1016\/S0140-6736(97)09137-X","volume":"351","author":"J Nussberger","year":"1998","unstructured":"Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A. Plasma bradykinin in angio-oedema. Lancet. 1998;351:1693\u20137.","journal-title":"Lancet"},{"issue":"3","key":"579_CR2","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jaci.2012.05.055","volume":"130","author":"K Bork","year":"2012","unstructured":"Bork K, Hardt J, Witzke G. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. J Allergy Clin Immunol. 2012;130(3):692\u20137.","journal-title":"J Allergy Clin Immunol"},{"issue":"72","key":"579_CR3","first-page":"1","volume":"15","author":"S Betschel","year":"2019","unstructured":"Betschel S, Badiou J, Binkley K, Borici-Mazi R, H\u00e9bert J, Kanani A, et al. The international\/Canadian hereditary angioedema guideline. Allergy Asthma Clin Immunol. 2019;15(72):1\u201329.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"579_CR4","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.amjmed.2005.09.064","volume":"119","author":"K Bork","year":"2006","unstructured":"Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med. 2006;119:267\u201374.","journal-title":"Am J Med"},{"issue":"21","key":"579_CR5","doi-asserted-by":"publisher","first-page":"00002","DOI":"10.1016\/j.anai.2021.01.002","volume":"S1081\u20131206","author":"E Lee","year":"2021","unstructured":"Lee E, Hsieh J, Borici-Mazi R, Caballero T, Kanani A, Lacuesta G, et al. Quality of life in patients with hereditary angioedema in Canada. Ann Allergy Asthma Immunol. 2021;S1081\u20131206(21):00002\u20138. https:\/\/doi.org\/10.1016\/j.anai.2021.01.002.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"579_CR6","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1808012","volume":"382","author":"P Busse","year":"2020","unstructured":"Busse P, Christiansen S. Hereditary angioedema. N Engl J Med. 2020;382:1136\u201348.","journal-title":"N Engl J Med"},{"issue":"1","key":"579_CR7","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/humu.23917","volume":"41","author":"D Ponard","year":"2020","unstructured":"Ponard D, Gaboriaud C, Charignon D, Ghannam A, Wagenaar-Bos I, Roem D, et al. SERPING1 mutation update: mutation spectrum and C1 Inhibitor phenotypes. Hum Mutat. 2020;41(1):38\u201357.","journal-title":"Hum Mutat"},{"issue":"1","key":"579_CR8","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1186\/s13023-020-01570-x","volume":"15","author":"K Bork","year":"2020","unstructured":"Bork K, Machnig T, Wulff K, Witzke G, Prusty S, Hardt J. Clinical features of genetically characterized types of hereditary angioedema with normal C1 inhibitor: a systematic review of qualitative evidence. Orphanet J Rare Dis. 2020;15(1):289.","journal-title":"Orphanet J Rare Dis"},{"key":"579_CR9","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1186\/1939-4551-3-S3-S39","volume":"3","author":"B Zuraw","year":"2010","unstructured":"Zuraw B. The pathophysiology of hereditary angioedema. World Allergy Organ J. 2010;3:S25\u20138.","journal-title":"World Allergy Organ J"},{"key":"579_CR10","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1056\/NEJMoa1605767","volume":"376","author":"A Banerji","year":"2017","unstructured":"Banerji A, Busse P, Shennak M, Lumry W, Davis-Lorton M, Wedner H, et al. Inhibiting plasma kallikrein for hereditary angioedema prophylaxis. N Engl J Med. 2017;376:717\u201328.","journal-title":"N Engl J Med"},{"key":"579_CR11","unstructured":"Takhzyro Product Monograph Sept 2020. https:\/\/www.takeda.com\/4ab39a\/siteassets\/en-ca\/home\/what-we-do\/our-medicines\/product-monographs\/takhzyro\/takhzyro-pm-en.pdf. Accessed 11 Mar 2021."},{"key":"579_CR12","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1001\/jama.2018.16773","volume":"320","author":"A Banerji","year":"2018","unstructured":"Banerji A, Riedl M, Bernstein J, Cicardi M, Longhurst H, Zuraw B, et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA. 2018;320:2108\u201321.","journal-title":"JAMA"},{"key":"579_CR13","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1016\/j.anai.2019.08.262","volume":"123","author":"D Johnston","year":"2019","unstructured":"Johnston D, Banerji A, Nurse C, Lu P, Ayg\u00f6ren-P\u00fcrs\u00fcn E, Kiani-Alikhan S, Soteres D, et al. Long-term safety of lanadelumab in hereditary angioedema (HAE): interim results from the HELP OLE Study. Ann Allergy Asthma Immunol. 2019;123:S30.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"579_CR14","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1056\/NEJMoa0805538","volume":"363","author":"B Zuraw","year":"2010","unstructured":"Zuraw B, Baker J, Cartwright W, Patel P, Tanner D, Redhead J, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med. 2010;363:513\u201322.","journal-title":"N Engl J Med"},{"issue":"12","key":"579_CR15","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1056\/NEJMoa1613627","volume":"376","author":"H Longhurst","year":"2017","unstructured":"Longhurst H, Cicardi M, Craig T, Bork K, Grattan C, Baker J, et al. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. N Engl J Med. 2017;376(12):1131\u201340.","journal-title":"N Engl J Med"},{"key":"579_CR16","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s40268-021-00337-4","volume":"21","author":"J Mendivil","year":"2021","unstructured":"Mendivil J, Malmen\u00e4s M, Haeussler K, Hunger M, Jain G, Devercelli G. Indirect comparison of lanadelumab and intravenous C1-INH using data from the HELP and CHANGE studies: Bayesian and frequentist analyses. Drugs R&D. 2021;21:113\u201321.","journal-title":"Drugs R&D"},{"issue":"5","key":"579_CR17","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1016\/j.anai.2018.09.186","volume":"121","author":"W Lumry","year":"2018","unstructured":"Lumry W, Busse P, Lu P, Jain G, Nurse C, Maurer M. Subcutaneous self-administration of lanadelumab for prophylactic treatment in patients with hereditary angioedema (HAE). Ann Allergy Asthma Immunol. 2018;121(5):S57. https:\/\/doi.org\/10.1016\/j.anai.2018.09.186.","journal-title":"Ann Allergy Asthma Immunol."}],"container-title":["Allergy, Asthma &amp; Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-021-00579-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13223-021-00579-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-021-00579-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T13:08:09Z","timestamp":1627045689000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacijournal.biomedcentral.com\/articles\/10.1186\/s13223-021-00579-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,23]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["579"],"URL":"https:\/\/doi.org\/10.1186\/s13223-021-00579-6","relation":{},"ISSN":["1710-1492"],"issn-type":[{"value":"1710-1492","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,23]]},"assertion":[{"value":"29 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a case series based on chart review. Upon review of The Unity Health Research Ethics board protocols and guidelines, it was determined that ethics approval was not required for this type of submission.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The case subjects freely gave informed consent to participate in this research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AI: This author declares that they have no competing interests.SB: Speaker and\/or advisor for CSL Behring, Shire\/Takeda. Funding of research CSL Behring.AK: Speaker and\/or advisor for CSL Behring, Shire\/Takeda. Funding of research from Takeda.GL: Speaker and\/or advisor for CSL Behring, Shire\/Takeda. Industry sponsored research with Takeda.CS: This author declares that they have no competing interests.MK: This author declares that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"78"}}